Activation of the EGFR/RAS/p42,44 MAPK axis as a convergent mechanism of resistance to CDK4/6 inhibitors in ER plus breast cancer

首页> 外文期刊>Intelligence: A Multidisciplinary Journal >Activation of the EGFR/RAS/p42,44 MAPK axis as a convergent mechanism of resistance to CDK4/6 inhibitors in ER plus breast cancer

【24h】

Activation of the EGFR/RAS/p42,44 MAPK axis as a convergent mechanism of resistance to CDK4/6 inhibitors in ER plus breast cancer

机译：EGFR / RAS / P42,44 MAPK轴作为ER加乳腺癌中CDK4 / 6抑制剂的抗性的会聚机制

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Intelligence: A Multidisciplinary Journal》 |2020年第2020期|共3页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类心理学;
关键词

相似文献

外文文献
中文文献
专利

1. Activation of the EGFR/RAS/p42,44 MAPK axis as a convergent mechanism of resistance to CDK4/6 inhibitors in ER plus breast cancer [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：EGFR / RAS / P42,44 MAPK轴作为ER加乳腺癌中CDK4 / 6抑制剂的抗性的会聚机制
2. Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling. [J] . Normanno N, Campiglio M, Maiello MR, Breast cancer research and treatment. . 2008,第1期

机译：对EGFR酪氨酸激酶抑制剂吉非替尼具有耐药性的乳腺癌细胞显示出MAPK信号的持续激活。
3. Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling [J] . Nicola Normanno, Manuela Campiglio, Monica R. Maiello, Breast Cancer Research and Treatment . 2008,第1期

机译：对EGFR酪氨酸激酶抑制剂吉非替尼具有耐药性的乳腺癌细胞显示出MAPK信号的持续激活
4. Simulations of the EGFR - KRAS - MAPK Signalling Network in Colon Cancer. Virtual Mutations and Virtual Treatments with Inhibitors Have More Important Effects Than a 10 Times Range of Normal Parameters and Rates Fluctuations [C] . Nicoletta Castagnino, Lorenzo Tortolina, Roberto Montagna, International Meeting on Computational Intelligence Methods for Bioinformatics and Biostatistics . 2010

机译：EGFR - KRAS - MAPK信号网络在结肠癌中的模拟。具有抑制剂的虚拟突变和虚拟处理具有比正常参数范围的10倍的更重要的效果和速率波动
5. Tamoxifen inhibits ERα positive breast cancer progression by disrupting the ERα-JMJD2B signaling axis [D] . Gupta, Rashi 2015

机译：他莫昔芬通过破坏ERα-JMJD2B信号轴来抑制ERα阳性乳腺癌的进展
6. LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer [O] . Xi Jin, Li-Ping Ge, Da-Qiang Li, 2020

机译：LncRNA TROJAN通过CD +转录激活在ER +乳腺癌中促进CDK4 / 6抑制剂的增殖和抵抗
7. LncRNA TROJAN promotes proliferation and resistance to CDK4/6 inhibitor via CDK2 transcriptional activation in ER+ breast cancer [O] . Xi Jin, Li-Ping Ge, Da-Qiang Li, 2020

机译：LNCRNA Trojan通过ER +乳腺癌的CDK2转录激活促进增殖和抗CDK4 / 6抑制剂

Activation of the EGFR/RAS/p42,44 MAPK axis as a convergent mechanism of resistance to CDK4/6 inhibitors in ER plus breast cancer

著录项

相似文献

相关主题

期刊订阅